StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Xilio Therapeutics's total assets was $154.25M at Jun 30, 2026. For fiscal 2025 it was $154.69M, up 117.6% from the year before. The highest annual figure on record is $218.06M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$154.69M+117.6%
FY2024Dec 31, 2024$71.08M+16.7%
FY2023Dec 31, 2023$60.93M-56.2%
FY2022Dec 31, 2022$139.17M-36.2%
FY2021Dec 31, 2021$218.06M+500.4%
FY2020Dec 31, 2020$36.32M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$154.25M+15.3%
Q1 FY2026Mar 31, 2026$163.49M+57.6%
Q4 FY2025Dec 31, 2025$154.69M+117.6%
Q3 FY2025Sep 30, 2025$133.69M+79.1%
Q2 FY2025Jun 30, 2025$133.81M+48.9%
Q1 FY2025Mar 31, 2025$103.72M+25.6%
Q4 FY2024Dec 31, 2024$71.08M+16.7%
Q3 FY2024Sep 30, 2024$74.66M-4.1%
Q2 FY2024Jun 30, 2024$89.87M-2.7%
Q1 FY2024Mar 31, 2024$82.61M-25.9%
Q4 FY2023Dec 31, 2023$60.93M-56.2%
Q3 FY2023Sep 30, 2023$77.84M-50.5%
Q2 FY2023Jun 30, 2023$92.36M-48.1%
Q1 FY2023Mar 31, 2023$111.51M-43.2%
Q4 FY2022Dec 31, 2022$139.17M-36.2%
Q3 FY2022Sep 30, 2022$157.41M+30.4%
Q2 FY2022Jun 30, 2022$178.13M+390.5%
Q1 FY2022Mar 31, 2022$196.35M–
Q4 FY2021Dec 31, 2021$218.06M–
Q3 FY2021Sep 30, 2021$120.73M–
Q4 FY2020Dec 31, 2020$36.32M–

More Xilio Therapeutics figures

See a number that looks wrong?